| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | -0.037 | 0.4 |
| mRNA | salermide | CTRPv2 | pan-cancer | AAC | -0.049 | 0.4 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | 0.031 | 0.4 |
| mRNA | AR-42 | GDSC1000 | pan-cancer | AAC | -0.027 | 0.4 |
| mRNA | ML311 | CTRPv2 | pan-cancer | AAC | -0.034 | 0.4 |
| mRNA | JW-480 | CTRPv2 | pan-cancer | AAC | 0.039 | 0.4 |
| mRNA | CHIR-99021 | GDSC1000 | pan-cancer | AAC | -0.027 | 0.4 |
| mRNA | THZ-2-49 | GDSC1000 | pan-cancer | AAC | -0.026 | 0.4 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | 0.074 | 0.4 |
| mRNA | Merck60 | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |